Mumbai, Maharashtra, India, February 2025 – Solara Active Pharma Sciences has announced the appointment of Vishal Mathur as its new Chief Business Officer (CBO). With 25 years of experience in the Active Pharmaceutical Ingredient (API) industry, Vishal brings a strong track record of business expansion, revenue growth, and strategic leadership in the pharmaceutical sector.
Prior to joining Solara, Vishal served as Chief Commercial Officer at Cohance Lifesciences, where he managed a $160 million business and drove 14% revenue growth across APIs, intermediates, and PFIs. His leadership played a key role in enhancing commercial performance and strengthening business operations.
Before Cohance, Vishal was Executive VP & Chief Marketing Officer at Emcure Pharmaceuticals, where he successfully doubled API business revenue and led sales, marketing, and portfolio development initiatives. His tenure at Glenmark Lifesciences, spanning 16 years, saw him rise to the position of Vice President – Sales & Marketing, where he played a pivotal role in driving $160 million in revenue, including the rapid commercialization of Favipiravir, a crucial molecule for COVID-19 treatment.
His earlier experiences include business development and marketing roles at Biocon and Kopran Ltd, where he honed his expertise in API sales, business expansion, and strategic partnerships.
Vishal holds an MBA in Marketing from Chetana’s Institute of Management, Mumbai, and a Master of Science in Organic Chemistry from Mohanlal Sukhadia University. His strong scientific and commercial acumen has been instrumental in leading high-growth API businesses.
About Solara Active Pharma Sciences
Solara Active Pharma Sciences is a leading API manufacturer, with over three decades of expertise in delivering high-quality pharmaceutical ingredients. Originating from the API expertise of Strides Shasun Ltd. and Sequent Scientific Ltd., Solara continues to drive customer-centric innovation, global regulatory compliance, and technical excellence. With 140+ scientists, two R&D centers, and four API manufacturing facilities, Solara is committed to advancing API manufacturing for global pharmaceutical markets.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
